Experienced in Ulcerative Colitis

Deliang A. Liu

No. 139 Middle Renmin Road, 
Changsha, CN 
Experienced in Ulcerative Colitis
No. 139 Middle Renmin Road, 
Changsha, CN 
OverviewLocationsClinical Research

Overview

Deliang Liu practices in Changsha, China. Liu is rated as an Experienced expert by MediFind in the treatment of Ulcerative Colitis. Their top areas of expertise are Achalasia, Uterine Fibroids, Esophageal Cancer, Endoscopy, and Stent Placement.

Their clinical research consists of co-authoring 175 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 9 articles in the study of Ulcerative Colitis.

Locations

No. 139 Middle Renmin Road, Changsha, 410011, China
Other Locations
132 Waihuan East Road, Guangzhou, 510006, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
View 1 Less Clinical Trial

175 Total Publications

Idiopathic AA amyloidosis presenting with initial abdominal pain: a case report and literature review.
Idiopathic AA amyloidosis presenting with initial abdominal pain: a case report and literature review.
Journal: Frontiers in medicine
Published: June 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Liu's expertise for a condition
ConditionClose
    View All 40 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile